HUP0001526A2 - Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions - Google Patents
Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositionsInfo
- Publication number
- HUP0001526A2 HUP0001526A2 HU0001526A HUP0001526A HUP0001526A2 HU P0001526 A2 HUP0001526 A2 HU P0001526A2 HU 0001526 A HU0001526 A HU 0001526A HU P0001526 A HUP0001526 A HU P0001526A HU P0001526 A2 HUP0001526 A2 HU P0001526A2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- responses
- medicinal preparations
- relates
- nucleozides
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 4
- 108090000695 Cytokines Proteins 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 238000002360 preparation method Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Abstract
A találmány nukleozidok és más vegyületek alkalmazására vonatkozikegymáshoz képest a Th1 és Th2 válaszok szelektív modulálása céljábólkülönböző megbetegedések kezelésénél és megelőzésénél alkalmazhatógyógyszerkészítmények előállításában. Egy másik aspektusban atalálmány a citokinek egyik csoportja vonatkozásában megnövekedettválasszal jellemezhető megbetegedések kezelésére alkalmas gyógyászatikészítményekre vonatkozik, amelyek a citokinek másik csoportjavonatkozásában megnövekedett választ kiváltó hatóanyagot tartalmaz.Egy további aspektusában a találmány tárgya egy vegyület alkalmazásaTh1 és Th2 citokin válaszok tekintetében abnormalitást mutatószervezetben a guanozintrifoszfát összegyűlő mennyiségét a Th1 és Th2válaszok közül az egyiket szelektíven csökkentő és a másikatugyanakkor nem szignifikáns mértékben csökkentő mértékben redukálókoncentrációban olyan gyógyászati készítmények előállítására, amelyekinverz módon módosítják a Th1 és Th2 válaszokat. A találmány tárgyamég nukleozidot tartalmazó szabályozott hatóanyag-leadásúgyógyszerkészítmények, amelyek főleg vírus- fertőzések ellenhatásosak. ÓThe invention relates to the use of nucleosides and other compounds in order to selectively modulate Th1 and Th2 responses in comparison to each other in the production of medicinal preparations that can be used in the treatment and prevention of various diseases. In another aspect, the invention relates to medicinal preparations suitable for the treatment of diseases characterized by an increased response to one group of cytokines, which contain an active ingredient that causes an increased response to another group of cytokines. In a further aspect, the subject of the invention is the use of a compound to reduce the amount of guanosine triphosphate that accumulates in Th1 in an organism showing abnormalities in Th1 and Th2 cytokine responses. and Th2 responses in a reducing concentration that selectively reduces one of them and, at the same time, does not significantly reduce the other, for the production of medicinal preparations that inversely modify Th1 and Th2 responses. The invention also relates to controlled-release medicinal preparations containing a nucleoside, which are mainly effective against viral infections. HE
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3609497P | 1997-01-17 | 1997-01-17 | |
| US4397497P | 1997-04-23 | 1997-04-23 | |
| US2858697P | 1997-04-23 | 1997-04-23 | |
| US5548797P | 1997-08-12 | 1997-08-12 | |
| PCT/US1998/000634 WO1998030223A1 (en) | 1997-01-17 | 1998-01-13 | Cytokine related treatments of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001526A2 true HUP0001526A2 (en) | 2001-05-28 |
| HUP0001526A3 HUP0001526A3 (en) | 2002-10-28 |
Family
ID=27487693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001526A HUP0001526A3 (en) | 1997-01-17 | 1998-01-13 | Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0998293A4 (en) |
| JP (3) | JP2002515892A (en) |
| KR (1) | KR20000070167A (en) |
| CN (3) | CN1253504A (en) |
| AU (1) | AU736075B2 (en) |
| BR (1) | BR9807473A (en) |
| CA (1) | CA2278158A1 (en) |
| HU (1) | HUP0001526A3 (en) |
| IL (1) | IL130497A0 (en) |
| NO (3) | NO993439L (en) |
| PL (1) | PL336579A1 (en) |
| SI (1) | SI9820003A (en) |
| SK (1) | SK94099A3 (en) |
| WO (1) | WO1998030223A1 (en) |
| YU (1) | YU61598A (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455690B1 (en) * | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| US6960569B2 (en) | 2000-08-17 | 2005-11-01 | Tripep Ab | Hepatitis C virus non-structural NS3/4A fusion gene |
| US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| JP5014122B2 (en) * | 2004-05-06 | 2012-08-29 | アメリカ合衆国 | Methods and compositions for the treatment of uveitis |
| SE0950633L (en) * | 2006-03-14 | 2009-09-03 | Wholesome Biopharm Pty Ltd | Method and composition for the treatment of allergic diseases |
| US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
| US10358458B2 (en) * | 2014-09-26 | 2019-07-23 | Riboscience Llc | 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
| NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
| CA2109528A1 (en) * | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
-
1998
- 1998-01-13 BR BR9807473A patent/BR9807473A/en unknown
- 1998-01-13 WO PCT/US1998/000634 patent/WO1998030223A1/en not_active Application Discontinuation
- 1998-01-13 YU YU61598A patent/YU61598A/en unknown
- 1998-01-13 KR KR1019997006393A patent/KR20000070167A/en not_active Application Discontinuation
- 1998-01-13 CN CN98801801A patent/CN1253504A/en active Pending
- 1998-01-13 IL IL13049798A patent/IL130497A0/en unknown
- 1998-01-13 CA CA002278158A patent/CA2278158A1/en not_active Abandoned
- 1998-01-13 SK SK940-99A patent/SK94099A3/en unknown
- 1998-01-13 AU AU60238/98A patent/AU736075B2/en not_active Ceased
- 1998-01-13 PL PL98336579A patent/PL336579A1/en unknown
- 1998-01-13 JP JP53124598A patent/JP2002515892A/en active Pending
- 1998-01-13 SI SI9820003A patent/SI9820003A/en not_active IP Right Cessation
- 1998-01-13 HU HU0001526A patent/HUP0001526A3/en unknown
- 1998-01-13 EP EP98903474A patent/EP0998293A4/en not_active Withdrawn
-
1999
- 1999-07-13 NO NO993439A patent/NO993439L/en not_active Application Discontinuation
-
2000
- 2000-07-22 CN CN00121912A patent/CN1312254A/en active Pending
- 2000-08-29 CN CN00126807A patent/CN1289594A/en active Pending
- 2000-08-31 NO NO20004327A patent/NO20004327D0/en unknown
- 2000-08-31 NO NO20004329A patent/NO20004329D0/en not_active Application Discontinuation
-
2001
- 2001-05-24 JP JP2001155321A patent/JP2002080490A/en active Pending
-
2003
- 2003-04-21 JP JP2003115258A patent/JP2004035546A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0998293A4 (en) | 2002-07-17 |
| CN1312254A (en) | 2001-09-12 |
| JP2002080490A (en) | 2002-03-19 |
| KR20000070167A (en) | 2000-11-25 |
| WO1998030223A1 (en) | 1998-07-16 |
| BR9807473A (en) | 2000-03-21 |
| PL336579A1 (en) | 2000-07-03 |
| YU61598A (en) | 2003-02-28 |
| CN1253504A (en) | 2000-05-17 |
| NO993439L (en) | 1999-09-13 |
| JP2004035546A (en) | 2004-02-05 |
| AU6023898A (en) | 1998-08-03 |
| NO20004329D0 (en) | 2000-08-31 |
| CA2278158A1 (en) | 1998-07-16 |
| SI9820003A (en) | 1999-06-30 |
| HUP0001526A3 (en) | 2002-10-28 |
| CN1289594A (en) | 2001-04-04 |
| EP0998293A1 (en) | 2000-05-10 |
| IL130497A0 (en) | 2000-06-01 |
| NO993439D0 (en) | 1999-07-13 |
| NO20004327D0 (en) | 2000-08-31 |
| SK94099A3 (en) | 2001-06-11 |
| JP2002515892A (en) | 2002-05-28 |
| NO20004329L (en) | 1999-09-13 |
| NO20004327L (en) | 1999-09-13 |
| AU736075B2 (en) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY104043A (en) | Therapeutic nucleosides. | |
| HUP0001526A2 (en) | Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions | |
| UA29429C2 (en) | Pharmaceutical composition for treatment of viral infections, method for preparation of composition, method for treatment or prophylaxis of aids in human | |
| MY104575A (en) | Therapeutic nucleosides. | |
| ATE282628T1 (en) | ORAL ACTIVE ADENOSIN KINASE INHIBITORS | |
| YU18899A (en) | Purine l-nucleosides, analogs and uses thereof | |
| MY103760A (en) | Therapeutic nucleosides | |
| MY130035A (en) | Antiviral compounds | |
| AU4690989A (en) | Antiviral cytosine and guanine derivatives | |
| UA40589C2 (en) | method for treating a human suffering from viral infection, pharmaceutical composition, combination of compounds for the preparation of medications and pharmaceutical combination | |
| HUP0302334A2 (en) | Antiviral prodrugs | |
| WO1993017020A3 (en) | Therapeutic nucleosides | |
| FR2700117B1 (en) | Application of anti-convulsants in the treatment of Parkinson's disease and parkinsonian syndromes. | |
| ES2052732T3 (en) | 2 ', 3'-DIDESOXI-3'-FLUOROTIMIDINE AND RELATED COMPOUNDS FOR THE TREATMENT OF ADENOVIRUS INFECTIONS. | |
| EP1536839A4 (en) | Method for treating diseases with omega interferon | |
| HUP0400553A2 (en) | Pharmaceutical compositions | |
| IL147477A (en) | Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemia | |
| IE892654L (en) | Therapeutic nucleosides | |
| BG100599A (en) | Antiviral form and therapeutical method | |
| HUP9900945A2 (en) | Nucleoside analogs in combinative therapy of herpes simplex infections | |
| ATE183508T1 (en) | THERAPEUTIC NUCLEOSIDES | |
| MY111746A (en) | Therapeutic nucleosides. | |
| EP1362593A4 (en) | Pharmaceutical composition for diabetic neuropathy | |
| HUP0302741A2 (en) | Stabilized brivudine topical formulations containing metal oxide pigments | |
| MY104976A (en) | Antiviral compounds |